Ultragenyx Pharmaceutical
RARE
173 hedge funds and large institutions have $2.49B invested in Ultragenyx Pharmaceutical in 2019 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 72 increasing their positions, 48 reducing their positions, and 26 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 48
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
0% more funds holding
Funds holding: 173 → 173 (0)
1% less capital invested
Capital invested by funds: $2.51B → $2.49B (-$23.5M)
0.94% less ownership
Funds ownership: 101.83% → 100.88% (-0.94%)
86% less call options, than puts
Call options by funds: $1.78M | Put options by funds: $12.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$43.7M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$35.7M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$9.29M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$8.73M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$8.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$81.5M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$36.8M |
| 3 |
O
OrbiMed
New York
|
-$35.7M |
| 4 |
HCM
Highline Capital Management
New York
|
-$12.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.7M |
RARE Hedge Fund Activity: Q4 2019 in Review
173 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q4 2019, worth a combined $2.49B — down 0.94% from $2.51B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RARE positions and 26 closed out — a net gain of 2 holders — while 72 added to existing stakes and 48 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $43.7M. The largest seller was Wellington Management Group, cutting an estimated $81.5M.
- 173 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q4 2019, unchanged from Q3 2019.
- Funds reported $2.49B of Ultragenyx Pharmaceutical stock for Q4 2019, down 0.94% quarter-over-quarter.
- 28 funds opened new Ultragenyx Pharmaceutical positions in Q4 2019 and 26 closed out, a net change of +2 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q4 2019 was Citadel Advisors, an estimated $43.7M added.
- The largest Ultragenyx Pharmaceutical seller in Q4 2019 was Wellington Management Group, an estimated $81.5M sold.
Based on aggregated 13F filings for Q4 2019.